
    
      This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design
      multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients
      with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection.
      Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or
      placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.

      A single arm, non-randomized, open-label phase is added to the protocol after completion of
      enrollment in the Randomized Phase of the study.

      The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
    
  